Erythropoietin in the critically ill: do we ask the right questions?

There is a plethora of experimental data on the potential therapeutic benefits of recombinant human erythropoietin (rhEPO) and its synthetic derivatives in critical care medicine, in particular in ischemia/reperfusion injury. Most of the recent clinical trials have not shown clear benefits, and, in...

Descripción completa

Detalles Bibliográficos
Autores principales: McCook, Oscar, Georgieff, Michael, Scheuerle, Angelika, Möller, Peter, Thiemermann, Christoph, Radermacher, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Viewpoint
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3682241/
https://www.ncbi.nlm.nih.gov/pubmed/23016869
http://dx.doi.org/10.1186/cc11430

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3682241/
https://www.ncbi.nlm.nih.gov/pubmed/23016869
http://dx.doi.org/10.1186/cc11430

Ejemplares similares